Takeda S - Search Results

1

Prognostic impact of venous thromboembolism in patients with Duchenne muscular dystrophy: Prospective multicenter 5-year cohort study.

Kimura K, Morita H, Daimon M, Kawata T, Nakao T, Lee SL, Hirokawa M, Ebihara A, Nakajima T, Ozawa T, Yonemochi Y, Aida I, Motoyoshi Y, Mikata T, Uchida I, Komori T, Kitao R, Nagata T, Takeda S, Komaki H, Segawa K, Takenaka K, Komuro I. Kimura K, et al. Among authors: takeda s. Int J Cardiol. 2015 Jul 15;191:178-80. doi: 10.1016/j.ijcard.2015.04.244. Epub 2015 May 1. Int J Cardiol. 2015. PMID: 25965627 No abstract available.

2

Two-layered appearance of noncompaction of the ventricular myocardium on magnetic resonance imaging.

Daimon Y, Watanabe S, Takeda S, Hijikata Y, Komuro I. Daimon Y, et al. Among authors: takeda s. Circ J. 2002 Jun;66(6):619-21. doi: 10.1253/circj.66.619. Circ J. 2002. PMID: 12074286 Free article.

3

Images in cardiovascular medicine. Transition from left ventricular hypertrophy to massive fibrosis in the cardiac variant of Fabry disease.

Hasegawa H, Takano H, Shindo S, Takeda S, Funabashi N, Nakagawa K, Toyozaki T, Kuwabara Y, Komuro I. Hasegawa H, et al. Among authors: takeda s. Circulation. 2006 Apr 25;113(16):e720-1. doi: 10.1161/CIRCULATIONAHA.105.584292. Circulation. 2006. PMID: 16636179 No abstract available.

4

[Stem cell based cell therapy for muscular dystrophy].

Takeda S. Takeda S. Rinsho Shinkeigaku. 2006 Nov;46(11):945-8. Rinsho Shinkeigaku. 2006. PMID: 17432228 Japanese.

5

Exon-skipping therapy for Duchenne muscular dystrophy.

Nakamura A, Takeda S. Nakamura A, et al. Among authors: takeda s. Neuropathology. 2009 Aug;29(4):494-501. doi: 10.1111/j.1440-1789.2009.01028.x. Epub 2009 May 22. Neuropathology. 2009. PMID: 19486303 Review.

6

[Exon skipping therapy for Duchenne muscular dystrophy by using antisense Morpholino].

Takeda S. Takeda S. Rinsho Shinkeigaku. 2009 Nov;49(11):856-8. doi: 10.5692/clinicalneurol.49.856. Rinsho Shinkeigaku. 2009. PMID: 20030230 Review. Japanese.

7

In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52-deficient mdx mouse.

Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T, Takeda S. Aoki Y, et al. Among authors: takeda s. Mol Ther. 2010 Nov;18(11):1995-2005. doi: 10.1038/mt.2010.186. Epub 2010 Sep 7. Mol Ther. 2010. PMID: 20823833 Free PMC article.

8

[Antisense oligos for muscular dystrophy].

Nagata T, Takeda S. Nagata T, et al. Among authors: takeda s. Rinsho Shinkeigaku. 2010 Nov;50(11):843. doi: 10.5692/clinicalneurol.50.843. Rinsho Shinkeigaku. 2010. PMID: 21921467 Japanese. No abstract available.

9

[Exon-skipping therapy for Duchenne muscular dystrophy].

Takeda S. Takeda S. Rinsho Shinkeigaku. 2011 Nov;51(11):914-6. doi: 10.5692/clinicalneurol.51.914. Rinsho Shinkeigaku. 2011. PMID: 22277414 Japanese.

10

Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery.

Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T, Duguez SM, Nagaraju K, Hoffman EP, Partridge T, Takeda S. Aoki Y, et al. Among authors: takeda s. Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13763-8. doi: 10.1073/pnas.1204638109. Epub 2012 Aug 6. Proc Natl Acad Sci U S A. 2012. PMID: 22869723 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,826 results

Search Page

Filters